Zynex Inc ZYXI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zynex to Present at the HC Wainwright Global Investment Conference
-
Zynex Obtains FDA clearance for new Pain Management Device
-
Zynex Reports Second Quarter 2024 Financial Results
-
Zynex Sets Second Quarter 2024 Earnings Call
-
Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces
Trading Information
- Previous Close Price
- $7.83
- Day Range
- $7.85–7.99
- 52-Week Range
- $7.04–13.77
- Bid/Ask
- $7.82 / $8.08
- Market Cap
- $250.77 Mil
- Volume/Avg
- 67,052 / 141,423
Key Statistics
- Price/Earnings (Normalized)
- 42.84
- Price/Sales
- 1.38
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 17.58%
Company Profile
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
- Sector
- Healthcare
- Industry
- Medical Distribution
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,101
- Website
- https://www.zynex.com
Comparables
Valuation
|
Metric
|
ZYXI
|
002901
|
301103
|
|---|---|---|---|
Price/Earnings (Normalized) | 42.84 | 907.94 | 681.95 |
Price/Book Value | 7.64 | 4.23 | 1.85 |
Price/Sales | 1.38 | 7.61 | 3.26 |
Price/Cash Flow | 22.21 | 35.09 | 23.64 |
Price/Earnings
ZYXI
002901
301103
Financial Strength
|
Metric
|
ZYXI
|
002901
|
301103
|
|---|---|---|---|
Quick Ratio | 2.99 | 1.68 | 8.53 |
Current Ratio | 4.06 | 2.95 | 9.13 |
Interest Coverage | 5.64 | 13.19 | 1.99 |
Quick Ratio
ZYXI
002901
301103
Profitability
|
Metric
|
ZYXI
|
002901
|
301103
|
|---|---|---|---|
Return on Assets (Normalized) | 5.97% | 1.51% | 0.21% |
Return on Equity (Normalized) | 17.67% | 2.20% | 0.26% |
Return on Invested Capital (Normalized) | 7.85% | 1.37% | −0.24% |
Return on Assets
ZYXI
002901
301103
Medical Distribution Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| McKesson Corp
MCK
| Vgwdvlvvz | Ywrmfdt | $62.9 Bil | |||
| Cencora Inc
COR
| Crllhpx | Fznwg | $43.1 Bil | |||
| Cardinal Health Inc
CAH
| Lrqnzfzg | Rzfskr | $27.1 Bil | |||
| Shanghai Pharmaceuticals Holding Co Ltd Class H
SHPMF
| — | Yqcbnbm | $10.0 Bil | |||
| Shanghai Pharmaceuticals Holding Co Ltd ADR repr Class H
SHPMY
| — | Kxmknwd | $10.0 Bil | |||
| Sinopharm Group Co Ltd ADR
SHTDY
| — | Jqrdqc | $9.1 Bil | |||
| Sinopharm Group Co Ltd
SHTDF
| — | Cvgzgrb | $9.1 Bil | |||
| Amplifon SpA Az nom Post Frazionamento
AMFPF
| — | Lssks | $6.4 Bil | |||
| Ebos Group Ltd ADR
EBOSY
| — | Bnmvqwt | $4.5 Bil | |||
| Medipal Holdings Corp ADR
MAHLY
| — | Dln | $3.7 Bil |
United States